Superworth

Verrica Pharmaceuticals EPS VRCA

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$1.67
Latest quarter, Q2 FY26
−$0.62
−3200% on a year earlier
Fiscal year 2025
−$1.61

Verrica Pharmaceuticals' earnings per share was −$1.67 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.62, down 3200% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.61n/a
FY2024−$15.39n/a
FY2023−$14.60n/a
FY2022−$8.20n/a
FY2021−$12.90n/a
FY2020−$17.10n/a
FY2019−$11.30n/a
FY2018−$21.10n/a
FY2017−$15.60n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.62−3200%−$1.67
Q1 FY26−$0.45n/a−$1.03
Q4 FY25−$0.57n/a−$1.61
Q3 FY25−$0.03n/a−$3.45
Q2 FY25$0.02n/a−$8.30
Q1 FY25−$1.03n/a−$12.02
Q4 FY24−$2.41n/a−$15.39
Q3 FY24−$4.88n/a−$18.28
Q2 FY24−$3.70n/a−$18.80
Q1 FY24−$4.40n/a−$17.50
Q4 FY23−$5.30n/a−$14.60
Q3 FY23−$5.40n/a−$10.70

Against its peers

Companies in Drug Manufacturers - General nearest Verrica Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
VRCAVerrica Pharmaceuticals−$1.67
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
Peer median$0.46

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Verrica Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.